Solana (NASDAQ:HSDT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Solana (NASDAQ:HSDT) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Solana Price Performance

HSDT stock opened at $3.75 on Friday. Solana has a 12 month low of $2.83 and a 12 month high of $1,200.00. The firm’s 50-day moving average is $10.68 and its 200 day moving average is $37.17. The company has a market capitalization of $4.04 million, a PE ratio of 0.00 and a beta of 1.00.

Solana (NASDAQ:HSDT) last issued its earnings results on Tuesday, November 18th. The company reported ($32.89) EPS for the quarter, topping analysts’ consensus estimates of ($50.50) by $17.61. Solana had a negative net margin of 39,358.88% and a negative return on equity of 699.93%. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.11 million.

Institutional Trading of Solana

A hedge fund recently bought a new stake in Solana stock. Armistice Capital LLC purchased a new stake in Solana Company (NASDAQ:HSDT) during the first quarter, according to its most recent filing with the SEC. The firm purchased 72,000 shares of the company’s stock, valued at approximately $29,000. Armistice Capital LLC owned 17.60% of Solana at the end of the most recent quarter. Hedge funds and other institutional investors own 18.63% of the company’s stock.

Solana Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.